Synonyms: CNTO-1275 | L04AC05 | Stelara® | TT-20
ustekinumab is an approved drug (FDA (2009), EMA (2009))
Compound class:
Antibody
Comment: Ustekinumab suppresses the immunomodulatory actions of both IL-12 and IL-23 on T-cell sub-populations. It binds to the common p40 subunit (IL12B) shared by these cytokines.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Biosimilars:
*After expiry of the period of exclusivity for the first interchangeable biosimilar product. |
Immunopharmacology Disease | |||
Disease | X-Refs | Comment | References |
Psoriasis |
Disease Ontology:
DOID:8893 |
An anti-IL-12B therapy approved to treat psoriasis. | |
Psoriatic arthritis |
Disease Ontology:
DOID:9008 |
An anti-IL-12B therapy approved to treat PsA. | |
Ulcerative colitis |
Disease Ontology:
DOID:8577 OMIM: 266600 Orphanet: ORPHA771 |
FDA approved for the treatment of moderate-severe UC in October 2019. Results from Phase 3 clinical trial NCT02407236 showed that ustekinumab was more effective than placebo as measured by induction and maintainance of clinical remission. | 2 |